ABSTRACT
OBJECTIVE@#To study the clinical characteristics, drug sensitivity of isolated strains, and risk factors of drug resistance in children with invasive pneumococcal disease (IPD).@*METHODS@#The clinical characteristics and drug sensitivity of the isolated strains of 246 hospitalized children with IPD in nine grade A tertiary children's hospitals from January 2016 to June 2018 were analyzed.@*RESULTS@#Of the 246 children with IPD, there were 122 males and 124 females. Their ages ranged from 1 day to 14 years, and among them, 68 (27.6%) patients were less than 1 year old, 54 (22.0%) patients were 1 to 2 years old, 97 (39.4%) patients were 2 to 5 years old, and 27 (11.0%) patients were 5 to 14 years old. Pneumonia with sepsis was the most common infection type (58.5%, 144/246), followed by bloodstream infection without focus (19.9%, 49/246) and meningitis (15.0%, 37/246). Forty-nine (19.9%) patients had underlying diseases, and 160 (65.0%) had various risk factors for drug resistance. The isolated Streptococcus pneumoniae strains were 100% sensitive to vancomycin, linezolid, moxifloxacin, and levofloxacin, 90% sensitive to ertapenem, ofloxacin, and ceftriaxone, but had a low sensitivity to erythromycin (4.2%), clindamycin (7.9%), and tetracycline (6.3%).@*CONCLUSIONS@#IPD is more common in children under 5 years old, especially in those under 2 years old. Some children with IPD have underlying diseases, and most of the patients have various risk factors for drug resistance. Pneumonia with sepsis is the most common infection type. The isolated Streptococcus pneumoniae strains are highly sensitive to vancomycin, linezolid, moxifloxacin, levofloxacin, ertapenem, and ceftriaxone in children with IPD.
Subject(s)
Child , Child, Preschool , Female , Humans , Infant , Male , Anti-Bacterial Agents , Ceftriaxone , Drug Resistance , Microbial Sensitivity Tests , Pneumococcal Infections , Streptococcus pneumoniaeABSTRACT
OBJECTIVE: To express the beta carbonic anhydrase (ß-CA) of Schistosoma japonicum, and analyze its catalytic activity. METHODS: The cDNA and amino sequence which may encode ß-CA of S. japonicum were obtained by the bioinformatics-method, and then the cDNA sequence was cloned into prokaryotic expression vector pET-32a (+) and expressed. After examining by SDS-PAGE and Western blotting, the recombinant protein was purified by Ni-affinity chromatography and the catalytic activity was determined. RESULTS: The sequence Sjp_0056790.1 took on the conservative position of ß-CAs. The PCR and restriction enzyme digestion confirmed the construction of recombinant plasmid pET-32a (+) -SjaCA. SDS-PAGE and Western blotting analyses showed that the molecular weight of recombinant protein was about 38 kDa as expected, and it could be recognized by anti-His tag antibody. The catalytic activity determining revealed that the recombinant protein SjaCA owned the carbonic anhydrase activity. CONCLUSIONS: Sjp_0056790.1 encodes the ß-CA of S. japonicum, and the ß-CA with catalytic activity is successfully expressed, so it lays a foundation for the subsequent research of pharmacological inhibition, providing theoretic basis for searching and developing a new feasible anti-schistosome drug.
Subject(s)
Carbonic Anhydrases/genetics , Helminth Proteins/genetics , Schistosoma japonicum/genetics , Amino Acid Sequence , Animals , Blotting, Western , Carbonic Anhydrases/chemistry , Carbonic Anhydrases/metabolism , Cloning, Molecular , Escherichia coli/genetics , Helminth Proteins/chemistry , Helminth Proteins/metabolism , Molecular Sequence Data , Schistosoma japonicum/chemistry , Schistosoma japonicum/metabolism , Sequence AlignmentABSTRACT
Renal tubulointerstitial fibrosis is the common ending of progreβsive renal disease. It is worth developing new ways to stop the progreβs of renal fibrosis. Peroxisome proliferator-activated receptor-γ (PPARγ) agonists have been studied to treat diabetic nephropathy, cisplatin-induced acute renal injury, ischemia reperfusion injury and adriamycin nephropathy. In this study, unilateral ureteral obstruction (UUO) was used to establish a different renal fibrosis model. PPAR? agonist pioglitazone was administrated by oral gavage and saline was used as control. At 7th and 14th day after the operation, mice were sacrificed for fibrosis test and T lymphocytes subsets test. Unexpectedly, through MASSON staining, immunohistochemistry for α-SMA, and Western blotting for a-SMA and PDGFR-β, we found that pioglitazone failed to attenuate renal fibrosis in UUO mice. However, flow cytometry showed that pioglitazone down-regulated Th1 cells, and up-regulated Th2 cells, Th17 cells and Treg cells. But the Th17/Treg ratio had no significant change by pioglitazone. Real-time PCR results showed that TGF-β and MCP-1 had no significant changes, at the same time, CD4(+) T cells associated cytokines were partially regulated by pioglitazone pretreatment. Taken together, pioglitazone failed to suppress renal fibrosis progression caused by UUO.
ABSTRACT
Renal tubulointerstitial fibrosis is the common ending of progressive renal disease. It is worth developing new ways to stop the progress of renal fibrosis. Peroxisome proliferator-activated receptor-γ (PPARγ) agonists have been studied to treat diabetic nephropathy, cisplatin-induced acute renal injury, ischemia reperfusion injury and adriamycin nephropathy. In this study, unilateral ureteral obstruction (UUO) was used to establish a different renal fibrosis model. PPAR? agonist pioglitazone was administrated by oral gavage and saline was used as control. At 7th and 14th day after the operation, mice were sacrificed for fibrosis test and T lymphocytes subsets test. Unexpectedly, through MASSON staining, immunohistochemistry for α-SMA, and Western blotting for a-SMA and PDGFR-β, we found that pioglitazone failed to attenuate renal fibrosis in UUO mice. However, flow cytometry showed that pioglitazone down-regulated Th1 cells, and up-regulated Th2 cells, Th17 cells and Treg cells. But the Th17/Treg ratio had no significant change by pioglitazone. Real-time PCR results showed that TGF-β and MCP-1 had no significant changes, at the same time, CD4(+) T cells associated cytokines were partially regulated by pioglitazone pretreatment. Taken together, pioglitazone failed to suppress renal fibrosis progression caused by UUO.
